Tariffs
← Earnings Calls
01
02
03
04 05 06
Tone
A1 A2 A3 A4
KVUE
FY2025 Q1
Softening
Kenvue Inc. earnings call
Buzzberg read
Tariffs to cause $150M gross 2025 cost impact
Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind.
Buzzberg read Tariffs to cause $150M gross 2025 cost impact Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind. Read full analysisCollapse analysis
Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind.
- FY25 adjusted EPS and operating margin guidance were both lowered to reflect the estimated $150M gross tariff impact, with EPS now expected to be flat year-over-year.
- FY25 net sales growth from FX improved to 1-3% from 0-2% due to a weaker dollar; organic sales growth outlook maintained at -4% to 0%.
- Consumption outpaced organic sales growth in all segments in Q1, signaling share gains and successful US price/trade initiatives, particularly in self-care and skin health.
Revenue$3.741BReported
EPS$0.24Reported
Gross margin57.95%Reported
Operating margin14.92%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Guidance
Q1 organic sales declined 0.2% as planned
Guidance
Company maintains 2025 organic sales growth outlook of 2-4%
Show 3 more callouts
Leadership
CFO transition: Amit Banati joins May 12
Demand
China destocking headwind expected to end by Q2
Margins
Adjusted operating margin now expected to contract slightly for full year
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $3.741B | Reported |
| EPS | $0.24 | Reported |
| Gross margin | 57.95% | Reported |
| Operating margin | 14.92% | Reported |
| Free cash flow | $0.249B | Reported |
| Capex | $0.179B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2025 | $0.00 | $0.00 | Lowered |
| Operating margin | FY2025 | 0% | 0% | Lowered |
| Revenue | FY2025 | $0B | $0B | Maintained |
AI, capex & demand read
Management read
Cautious
Management acknowledged a dynamic and fluid macro environment, including tariffs, category deceleration, and seasonal shifts, while expressing confidence in their strategic plan and back-half acceleration.
all 8 named companies below
Companiesreturns since call
Partners
Partners
Thibaut Mongone
Kenvue's full exit from J&J's transition services agreements marks its independence, potentially freeing it from legacy overhead but also ending a revenue stream for J&J.
Evidence
“In April, we reached a major operational milestone, completing our transition services agreement program, finalizing the exit of more than 2,300 TSAs as per plan and without any disruption to our business.”
Supply chain
Supply chain
Thibaut Mongone
The incoming CFO's history at Kellanova is mentioned in a Q&A; it's a reference to his background, not a statement about either company's current trajectory.
Evidence
“he's probably most closely associated today with seeing Kellogg through the Kellenova WK Kellogg separation and the subsequent sale of Kellenova to Mars.”
Supply chain
Thibaut Mongone
April US retail orders tightened, which combined with a delayed allergy/sun season, may shift volumes into later quarters. — This signals the consumer staples sector overall faces a near-term demand pull-forward/deferral dynamic, potentially pressuring H1 sales for peers while setting up a potentially stronger H2.
Evidence
“from a macro point of view, we have seen some retailers tightening order management in April in the US. So these two factors may shift volumes from one quarter to the next.”
Supply chain
Thibaut Mongone
Consumption outpaced organic sales growth across all segments in Q1, driven by US price/trade investment, indicating Kenvue is gaining share and household penetration in the US despite retailer destocking. — This suggests the US price/trade investments are driving market share gains for Kenvue, indicating a competitive pricing response from Kenvue that could pressure US market share for peers like Church & Dwight and L'Oreal.
Evidence
“Globally, we are activating our five extraordinary powers, driving stronger consumption performance for the company in Q1 relative to Q4. In fact, consumption for the quarter outpaced organic sales growth across each of our three segments.”
External signals
Supply-chain alpha · 4returns since call
Kenvue's gross tariff impact is ~$150M, with ~two-thirds coming from China (at a 145% rate), and the largest import flow being finished goods from Canada (netting to <10% impact after MCA exemptions).
Evidence
“The biggest importer is Canada, Canada into the US, and most of that is finished goods... It's about two-thirds of the analyzed impact at the current rate of 145%. To give a little more color, two-thirds is finished products, about one-thi…”
April US retail orders tightened, which combined with a delayed allergy/sun season, may shift volumes into later quarters.
Consumption outpaced organic sales growth across all segments in Q1, driven by US price/trade investment, indicating Kenvue is gaining share and household penetration in the US despite retailer destocking.
Tylenol gained share for the 11th straight quarter and was the only brand in its category gaining value and volume share, while Zyrtec grew both value and volume share.
Evidence
“we capitalize on the seasonal spike in the U.S. and strengthen Tylenol's number one position, gaining share for the 11th straight quarter and widening the gap further with competition. And once again, Tylenol was the only brand in the cate…”
Methodology & coverage
Management-only analysis. All 8 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.